{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:58:23Z","timestamp":1787497103868,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both angiotensin II type I receptor blockers (ARBs) and calcium channel blockers (CCBs) are widely used antihypertensive drugs. Many clinical studies have demonstrated and compared the organ-protection effects and adverse events of these drugs. However, few large-scale studies have focused on the effect of these drugs as monotherapy on laboratory parameters. We evaluated and compared the effects of ARB and CCB monotherapy on clinical laboratory parameters in patients with concomitant hypertension and type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the Clinical Data Warehouse of Nihon University School of Medicine obtained between Nov 1, 2004 and July 31, 2011, to identify cohorts of new ARB users (n\u2009=\u2009601) and propensity-score matched new CCB users (n\u2009=\u2009601), with concomitant mild to moderate hypertension and type 2 diabetes mellitus. We used a multivariate-adjusted regression model to adjust for differences between ARB and CCB users, and compared laboratory parameters including serum levels of triglyceride (TG), total cholesterol (TC), non-fasting blood glucose, hemoglobin A1c (HbA1c), sodium, potassium, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), hemoglobin and hematocrit, and white blood cell (WBC), red blood cell (RBC) and platelet (PLT) counts up to 12\u2009months after the start of ARB or CCB monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found a significant reduction of serum TC, HbA1c, hemoglobin and hematocrit and RBC count and a significant increase of serum potassium in ARB users, and a reduction of serum TC and hemoglobin in CCB users, from the baseline period to the exposure period. The reductions of RBC count, hemoglobin and hematocrit in ARB users were significantly greater than those in CCB users. The increase of serum potassium in ARB users was significantly greater than that in CCB users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggested that hematological adverse effects and electrolyte imbalance are greater with ARB monotherapy than with CCB monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1475-2840-11-53","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T14:23:34Z","timestamp":1337264614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes"],"prefix":"10.1186","volume":"11","author":[{"given":"Yayoi","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"483_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008, 148: 30-48.","journal-title":"Ann Intern Med"},{"key":"483_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003, 362: 759-766. 10.1016\/S0140-6736(03)14282-1.","journal-title":"Lancet"},{"key":"483_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005, 366: 895-906. 10.1016\/S0140-6736(05)67185-1.","journal-title":"Lancet"},{"key":"483_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.ki.5002623","volume":"72","author":"T Fujita","year":"2007","unstructured":"Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007, 72: 1543-1549. 10.1038\/sj.ki.5002623.","journal-title":"Kidney Int"},{"key":"483_CR5","first-page":"547","volume":"5","author":"SA Sadjadi","year":"2009","unstructured":"Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS: A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009, 5: 547-552.","journal-title":"Ther Clin Risk Manag"},{"key":"483_CR6","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.transproceed.2005.03.085","volume":"37","author":"A Ersoy","year":"2005","unstructured":"Ersoy A, Kahvecioglu S, Ersoy C, Cift A, Dilek K: Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Transplant Proc. 2005, 37: 2148-2150. 10.1016\/j.transproceed.2005.03.085.","journal-title":"Transplant Proc"},{"key":"483_CR7","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1016\/j.transproceed.2010.07.053","volume":"42","author":"V L\u00f3pez","year":"2010","unstructured":"L\u00f3pez V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Mart\u00ednez D, Hernandez D: Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc. 2010, 42: 2883-2885. 10.1016\/j.transproceed.2010.07.053.","journal-title":"Transplant Proc"},{"key":"483_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1751-7176.2008.00006.x","volume":"10","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG: Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. J Clin Hypertens (Greenwich). 2008, 10: 716-722. 10.1111\/j.1751-7176.2008.00006.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"483_CR9","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25: 1105-1187. 10.1097\/HJH.0b013e3281fc975a.","journal-title":"J Hypertens"},{"key":"483_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11883-011-0160-9","volume":"13","author":"G Reboldi","year":"2011","unstructured":"Reboldi G, Gentile G, Angeli F, Verdecchia P: Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atheroscler Rep. 2011, 13: 176-185. 10.1007\/s11883-011-0160-9.","journal-title":"Curr Atheroscler Rep"},{"key":"483_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2796.1994.tb01080.x","volume":"235","author":"CE Mogensen","year":"1994","unstructured":"Mogensen CE: Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med. 1994, 235: 297-316. 10.1111\/j.1365-2796.1994.tb01080.x.","journal-title":"J Intern Med"},{"key":"483_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007, 369: 201-207. 10.1016\/S0140-6736(07)60108-1.","journal-title":"Lancet"},{"key":"483_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2840-6-26","volume":"6","author":"N Kitamura","year":"2007","unstructured":"Kitamura N, Takahashi Y, Yamadate S, Asai S: Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007, 6: 26-10.1186\/1475-2840-6-26.","journal-title":"Cardiovasc Diabetol"},{"key":"483_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","volume":"51","author":"T Ogihara","year":"2008","unstructured":"Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008, 51: 393-398. 10.1161\/HYPERTENSIONAHA.107.098475.","journal-title":"Hypertension"},{"key":"483_CR15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004, 363: 2022-2231. 10.1016\/S0140-6736(04)16451-9.","journal-title":"Lancet"},{"key":"483_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","volume":"48","author":"S Julius","year":"2006","unstructured":"Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR: The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006, 48: 385-391. 10.1161\/01.HYP.0000236119.96301.f2.","journal-title":"Hypertension"},{"key":"483_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00228-011-1088-2","volume":"68","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Nishida Y, Asai S: Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol. 2011, 68: 123-129.","journal-title":"Eur J Clin Pharmacol"},{"key":"483_CR18","first-page":"51","volume-title":"Analysis of Observational Health Care Data Using SAS","author":"PC Austin","year":"2010","unstructured":"Austin PC, Chiu M, Ko DT, Goeree R, Tu JV: Propensity Score Matching for Estimating Treatment Effects. Analysis of Observational Health Care Data Using SAS. Edited by: Faries DE, Leon AC, Haro JM, Obenchain RL. 2010, SAS Press, Cary, 51-84."},{"key":"483_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1475-2840-10-45","volume":"10","author":"Y Takahashi","year":"2011","unstructured":"Takahashi Y, Nishida Y, Nakayama T, Asai S: Adverse effect profile of trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol. 2011, 10: 45-10.1186\/1475-2840-10-45.","journal-title":"Cardiovasc Diabetol"},{"key":"483_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55. 10.1093\/biomet\/70.1.41.","journal-title":"Biometrika"},{"key":"483_CR21","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.transproceed.2004.09.014","volume":"37","author":"CA Flores","year":"2005","unstructured":"Flores CA, Ardiles LG, Aros CA, Mu\u00f1oz CC, Schneider HO, Ram\u00edrez JA, Jerez V, Valderrama MG, Mezzano SA: Valsartan-induced hematocrit changes in renal transplant patients. Transplant Proc. 2005, 37: 1586-1588. 10.1016\/j.transproceed.2004.09.014.","journal-title":"Transplant Proc"},{"key":"483_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1034\/j.1399-0012.2002.01127.x","volume":"16","author":"A Ersoy","year":"2002","unstructured":"Ersoy A, Dilek K, Usta M, Yavuz M, G\u00fcll\u00fcl\u00fc M, Oktay B, Yurtkuran M: Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin Transplant. 2002, 16: 202-205. 10.1034\/j.1399-0012.2002.01127.x.","journal-title":"Clin Transplant"},{"key":"483_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0014-2999(98)00451-8","volume":"354","author":"I Naeshiro","year":"1998","unstructured":"Naeshiro I, Sato K, Chatani F, Sato S: Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol. 1998, 354: 179-187. 10.1016\/S0014-2999(98)00451-8.","journal-title":"Eur J Pharmacol"},{"key":"483_CR24","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1093\/ndt\/gfk058","volume":"21","author":"RN Formica","year":"2006","unstructured":"Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ: A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant. 2006, 21: 1389-1394. 10.1093\/ndt\/gfk058.","journal-title":"Nephrol Dial Transplant"},{"key":"483_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.clinthera.2011.04.011","volume":"33","author":"D Kurnik","year":"2011","unstructured":"Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R: Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Clin Ther. 2011, 33: 456-464. 10.1016\/j.clinthera.2011.04.011.","journal-title":"Clin Ther"},{"key":"483_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1161\/HYPERTENSIONAHA.108.119404","volume":"52","author":"JW Eriksson","year":"2008","unstructured":"Eriksson JW, Jansson PA, Carlberg B, H\u00e4gg A, Kurland L, Svensson MK, Ahlstr\u00f6m H, Str\u00f6m C, L\u00f6nn L, Ojbrandt K, Johansson L, Lind L: Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of candesartan (MEDICA) Study. Hypertension. 2008, 52: 1030-1037. 10.1161\/HYPERTENSIONAHA.108.119404.","journal-title":"Hypertension"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0168-8227(02)00102-X","volume":"58","author":"H Kavgaci","year":"2002","unstructured":"Kavgaci H, Sahin A, Onder Ersoz H, Erem C, Ozdemir F: The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract. 2002, 58: 19-25. 10.1016\/S0168-8227(02)00102-X.","journal-title":"Diabetes Res Clin Pract"},{"key":"483_CR28","first-page":"22","volume":"36","author":"MA Munger","year":"2011","unstructured":"Munger MA: Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P T. 2011, 36: 22-40.","journal-title":"P T"},{"key":"483_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4682-3-1","volume":"3","author":"TG Marshall","year":"2006","unstructured":"Marshall TG, Lee RE, Marshall FE: Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model. 2006, 3: 1-10.1186\/1742-4682-3-1.","journal-title":"Theor Biol Med Model"},{"key":"483_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.diabres.2008.07.003","volume":"82","author":"A Yamana","year":"2008","unstructured":"Yamana A, Arita M, Furuta M, Shimajiri Y, Sanke T: The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. Diabetes Res Clin Pract. 2008, 82: 127-131. 10.1016\/j.diabres.2008.07.003.","journal-title":"Diabetes Res Clin Pract"},{"key":"483_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12325-011-0040-2","volume":"28","author":"Y Mori","year":"2011","unstructured":"Mori Y, Tanaka T, Matsuura K, Yokoyama J, Utsunomiya K: Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther. 2011, 28: 698-706. 10.1007\/s12325-011-0040-2.","journal-title":"Adv Ther"},{"key":"483_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3343\/alm.2012.32.1.17","volume":"32","author":"N Sinha","year":"2012","unstructured":"Sinha N, Mishra TK, Singh T, Gupta N: Effect of iron deficiency anemia on hemoglobin A1c levels. Ann Lab Med. 2012, 32: 17-22. 10.3343\/alm.2012.32.1.17.","journal-title":"Ann Lab Med"},{"key":"483_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1753-0407.2010.00100.x","volume":"3","author":"ES Ford","year":"2011","unstructured":"Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT: Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011, 3: 67-73. 10.1111\/j.1753-0407.2010.00100.x.","journal-title":"J Diabetes"},{"key":"483_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1291\/hypres.31.841","volume":"31","author":"T Nakamura","year":"2008","unstructured":"Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K: Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res. 2008, 31: 841-850. 10.1291\/hypres.31.841.","journal-title":"Hypertens Res"},{"key":"483_CR35","volume-title":"Behre HM: Testosterone: action, deficiency, substitution","author":"E Nieschlag","year":"1998","unstructured":"Nieschlag E: Behre HM: Testosterone: action, deficiency, substitution. 1998, Springer, Berlin, 2","edition":"2"},{"key":"483_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1475-2840-9-38","volume":"9","author":"Y Nishida","year":"2010","unstructured":"Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S: Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2010, 9: 38-10.1186\/1475-2840-9-38.","journal-title":"Cardiovasc Diabetol"},{"key":"483_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1475-2840-10-74","volume":"10","author":"Y Nishida","year":"2011","unstructured":"Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S: Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol. 2011, 10: 74-10.1186\/1475-2840-10-74.","journal-title":"Cardiovasc Diabetol"},{"key":"483_CR38","first-page":"21","volume":"47","author":"SM Kyvelou","year":"2006","unstructured":"Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol. 2006, 47: 21-28.","journal-title":"Hellenic J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2840-11-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:24:52Z","timestamp":1630509892000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/1475-2840-11-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1186\/1475-2840-11-53","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]},"assertion":[{"value":"11 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}